Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for ...

Frequent distressing dreams are linked to faster biologic aging and an increased risk for premature death, independent of ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Most recently, the drug pulled around 13.3 billion Japanese yen ($87 million) in the third quarter of Eisai’s 2024 fiscal year, which will end March 31. Leqembi collected sales of 29.6 billion ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss ...

Eisai to Divest Rights for Pariet in China to Peak Pharma TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai Co., ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission: Tokyo Wednesday, April 2, 2025, 16:00 Hrs [IST] Eisai C ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.